Prestige Consumer Healthcare (PBH)
NYSE:PBH
Top Page
Prestige Consumer Healthcare
(NYSE:PBH)
Select Model
Select Model
Rating:69Neutral
Price Target:
$57.00
▲(8.61% Upside)
Action:DowngradedDate:04/03/26
The score is driven primarily by strong cash flow quality and solid recent profitability with improved leverage, reinforced by earnings-call guidance that maintained free cash flow targets and highlighted margin strength. These positives are partially offset by weak technicals (downtrend and bearish momentum), continued near-term revenue headwinds (supply constraints/category softness), and added leverage/execution risk from the Breathe Right acquisition.
Positive Factors
Free cash flow generation
Consistent operating cash flow (~$230–$277M) and high free cash flow conversion (~0.91–0.97) provide durable internal funding. That repeatable FCF supports disciplined buybacks, M&A, capex for supply fixes and deleveraging, increasing financial flexibility through cycles.
Negative Factors
Weak and volatile revenue growth
Pronounced revenue weakness and volatility reduces operating leverage and makes multi-period planning difficult. Persistent top-line declines constrain the ability to scale SG&A and trade spend efficiently, increasing reliance on acquisitions and cost actions to sustain earnings and cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Consistent operating cash flow (~$230–$277M) and high free cash flow conversion (~0.91–0.97) provide durable internal funding. That repeatable FCF supports disciplined buybacks, M&A, capex for supply fixes and deleveraging, increasing financial flexibility through cycles.
Read all positive factors
Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.48B
Dividend YieldN/A
Average Volume (3M)456.76K
Price to Earnings (P/E)15.8
Beta (1Y)0.28
Revenue Growth-0.02%
EPS Growth-1.87%
CountryUS
Employees600
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.14
Shares Outstanding47,318,730
10 Day Avg. Volume504,397
30 Day Avg. Volume456,760
Financial Highlights & Ratios
PEG Ratio7.62
Price to Book (P/B)2.33
Price to Sales (P/S)3.76
P/FCF Ratio17.56
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue3.21
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda10.46
Forecast
1Y Price Target
$93.67Price Target Upside78.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.8
Revenue Forecast (FY)$1.13B
Prestige Consumer Healthcare Business Overview & Revenue Model
Company Description
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in t...
How the Company Makes Money
PBH makes money primarily by selling branded OTC consumer healthcare and personal care products to retail and e-commerce customers (typically on a wholesale basis, with retailers then selling to end consumers). Revenue is driven by (1) volume of p...
Prestige Consumer Healthcare Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call balanced clear operational and financial strengths — notably strong free cash flow (+~13% YTD), margin expansion (first nine months gross margin +50 bps and Q4 guide to ~57%), strategic acquisition (Pillar Five) to remedy long-standing Clear Eyes supply issues, and opportunistic buybacks — against persistent near-term headwinds driven by Clear Eyes supply constraints, category softness in analgesics/cough & cold/lice, a $10M supplier loan write-off, and volatile retailer ordering patterns. Management projects continued sequential supply improvements and maintained full-year free cash flow and narrowed EPS and revenue guidance, indicating confidence in financial resilience while acknowledging ongoing execution and demand uncertainties.Positive Updates
Solid Q3 Revenue and Slight Beat to Forecast
Q3 sales of $283.4 million (down 2.4% vs. prior year, or down 2.2% excluding FX) were slightly ahead of company expectations, demonstrating resilience amid a volatile consumer backdrop.
Negative Updates
Clear Eyes Supply Constraints Impacting Sales
Limited Clear Eyes production materially contributed to lower eye and ear care sales and was a primary driver of the year-to-date organic revenue decline. Management notes restocking and SKU assortment recovery will take time (into fiscal 2027) and will involve one-time transition investments.
Read all updates
Q3-2026 Updates
Positive
Negative
Solid Q3 Revenue and Slight Beat to Forecast
Q3 sales of $283.4 million (down 2.4% vs. prior year, or down 2.2% excluding FX) were slightly ahead of company expectations, demonstrating resilience amid a volatile consumer backdrop.
Read all positive updates
Company Guidance
Management guided fiscal 2026 revenue of approximately $1.1 billion, adjusted diluted EPS of about $4.54, and maintained free cash flow guidance of $245 million or more; they expect Q4 adjusted gross margin of ~57%, a tariff outlook of roughly $5 million, Q4 interest expense of ~ $11 million, a normalized tax rate of ~24%, and a share count just under 48 million. Management said Clear Eyes supply should continue to improve sequentially in Q4 (third consecutive quarter) and through calendar 2026; YTD/Q3 metrics include Q3 sales of $283.4 million (down 2.4% YoY, -2.2% ex‑FX), nine‑month organic revenue down 3.9% (North America -4.4%, International -90 bps), Q3 gross margin 55.5% (YTD gross margin 55.7%, +50 bps YoY), Q3 adjusted EPS $1.14 (vs. $1.22 prior year) and nine‑month adjusted EPS $3.16 (vs. $3.20), adjusted EBITDA margin in the low‑30s, YTD free cash flow $208.8 million (up 12.9% YoY), net debt of ~ $1.0 billion (covenant leverage ~2.6x / mid‑2s), share repurchases of over $150 million YTD (~nearly 5% of shares, including ~ $46 million in Q3), a Pillar Five acquisition for just over $110 million, an approximate $10 million supplier‑loan write‑off, A&M guidance just under 14% of sales (14.1% YTD) and full‑year adjusted G&A of just over 10% of sales.Prestige Consumer Healthcare Financial Statement Overview
Summary
Income Statement
77
Positive
Balance Sheet
74
Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 1.14B | 1.13B | 1.13B | 1.09B | 943.37M |
| Gross Profit | 622.30M | 634.46M | 624.45M | 625.29M | 620.65M | 547.47M |
| EBITDA | 338.53M | 361.99M | 373.86M | 7.87M | 358.84M | 316.61M |
| Net Income | 186.50M | 214.60M | 209.34M | -82.31M | 205.38M | 164.68M |
Balance Sheet | ||||||
| Total Assets | 3.49B | 3.40B | 3.32B | 3.35B | 3.67B | 3.43B |
| Cash, Cash Equivalents and Short-Term Investments | 62.37M | 97.88M | 46.47M | 58.49M | 27.18M | 32.30M |
| Total Debt | 1.08B | 1.04B | 1.14B | 1.37B | 1.51B | 1.51B |
| Total Liabilities | 1.67B | 1.57B | 1.66B | 1.91B | 2.09B | 2.07B |
| Stockholders Equity | 1.83B | 1.83B | 1.66B | 1.45B | 1.58B | 1.36B |
Cash Flow | ||||||
| Free Cash Flow | 267.19M | 243.29M | 239.38M | 221.93M | 250.28M | 213.36M |
| Operating Cash Flow | 276.63M | 251.51M | 248.93M | 229.72M | 259.92M | 235.61M |
| Investing Cash Flow | -136.91M | -17.45M | -20.11M | -11.58M | -256.51M | -22.24M |
| Financing Cash Flow | -129.45M | -182.07M | -241.01M | -185.85M | -7.57M | -279.42M |
Prestige Consumer Healthcare Technical Analysis
Negative
52.48
Price Trends
64.66
Negative
63.12
Negative
65.92
Negative
Market Momentum
-2.45
Positive
22.17
Positive
9.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Negative. The current price of 52.48 is below the 20-day moving average (MA) of 61.27, below the 50-day MA of 64.66, and below the 200-day MA of 65.92, indicating a bearish trend. The MACD of -2.45 indicates Positive momentum. The RSI at 22.17 is Positive, neither overbought nor oversold. The STOCH value of 9.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBH.
Prestige Consumer Healthcare Risk Analysis
Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prestige Consumer Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $108.31B | 21.30 | -245.27% | 0.37% | 17.23% | 66.17% | |
71 Outperform | $2.41B | 38.14 | 25.85% | ― | 18.68% | ― | |
69 Neutral | $2.48B | 15.81 | 11.29% | ― | -0.02% | -1.87% | |
65 Neutral | $50.37B | 25.74 | -58.93% | 0.98% | 4.37% | 28.48% | |
65 Neutral | $8.48B | 23.11 | 11.92% | ― | 3.51% | 29.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PBH
Prestige Consumer Healthcare
52.48
-30.37
-36.66%
CAH
Cardinal Health
214.05
85.87
66.99%
HSIC
Henry Schein
73.94
8.47
12.94%
MCK
McKesson
884.28
203.86
29.96%
GRDN
Guardian Pharmacy Services, Inc. Class A
37.99
16.74
78.78%
Prestige Consumer Healthcare Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Prestige Consumer to Acquire Breathe Right Brand Portfolio
Positive
Mar 20, 2026
On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Consumer Healthcare, signed an asset purchase agreement to acquire from Foundation Consumer Brands a portfolio of over-the-counter health products centered on Breathe Right ...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
Prestige Consumer Healthcare Reports Q3 Results, Narrows Outlook
Negative
Feb 5, 2026
On February 5, 2026, Prestige Consumer Healthcare reported that third-quarter fiscal 2026 revenue for the period ended December 31, 2025 declined 2.4% year-on-year to $283.4 million, as constrained supply of its Clear Eyes products weighed on its ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.